Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 275

1.

Deletion of interleukin 1 receptor associated kinase 1 (IRAK1) improves glucose tolerance primarily by increasing insulin sensitivity in skeletal muscle.

Sun XJ, Kim SP, Zhang D, Sun H, Cao Q, Lu X, Ying Z, Li L, Henry RR, Ciaraldi TP, Taylor SI, Quon MJ.

J Biol Chem. 2017 Jun 1. pii: jbc.M117.779108. doi: 10.1074/jbc.M117.779108. [Epub ahead of print]

2.

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

Müller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M.

Cardiovasc Diabetol. 2017 May 25;16(1):70. doi: 10.1186/s12933-017-0552-4.

3.

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

Cariou B, Leiter LA, Müller-Wieland D, Bigot G, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Letierce A, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M.

Diabetes Metab. 2017 Mar 24. pii: S1262-3636(17)30008-3. doi: 10.1016/j.diabet.2017.01.004. [Epub ahead of print]

4.

Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.

Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L.

Diabetes Obes Metab. 2017 Jun;19(6):814-821. doi: 10.1111/dom.12882. Epub 2017 Mar 27.

PMID:
28098426
5.

Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.

Mudaliar S, Henry RR, Ciaraldi TP, Armstrong DA, Burke PM, Pettus JH, Garhyan P, Choi SL, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen NK, Sinha VP, Linnebjerg H, Jacober SJ.

Diabetes Obes Metab. 2016 Oct;18 Suppl 2:17-24. doi: 10.1111/dom.12753.

PMID:
27723226
6.

Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.

Espinoza SE, Wang CP, Tripathy D, Clement SC, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Stentz FB, Reaven PD, DeFronzo RA, Musi N.

Age (Dordr). 2016 Dec;38(5-6):485-493. Epub 2016 Sep 1.

7.
8.

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors.

Polonsky WH, Henry RR.

Patient Prefer Adherence. 2016 Jul 22;10:1299-307. doi: 10.2147/PPA.S106821. eCollection 2016. Review.

9.

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.

Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, Müller-Wieland D, Henry RR, Cariou B, Baccara-Dinet MT, Pordy R, Merlet L, Eckel RH.

Eur Heart J. 2016 Oct 14;37(39):2981-2989. Epub 2016 Jul 26.

10.

Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes.

Ciaraldi TP, Ryan AJ, Mudaliar SR, Henry RR.

PLoS One. 2016 Jul 25;11(7):e0158209. doi: 10.1371/journal.pone.0158209. eCollection 2016.

11.

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.

Mudaliar S, Alloju S, Henry RR.

Diabetes Care. 2016 Jul;39(7):1115-22. doi: 10.2337/dc16-0542.

PMID:
27289124
12.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.

Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR.

Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.

PMID:
27082665
13.

Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.

Peters AL, Henry RR, Thakkar P, Tong C, Alba M.

Diabetes Care. 2016 Apr;39(4):532-8. doi: 10.2337/dc15-1995.

PMID:
26989182
14.

Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.

Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA.

J Clin Endocrinol Metab. 2016 May;101(5):2056-62. doi: 10.1210/jc.2015-4202. Epub 2016 Mar 16.

PMID:
26982008
15.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE).

Endocr Pract. 2016 Jan;22(1):84-113. doi: 10.4158/EP151126.CS. No abstract available.

PMID:
26731084
16.

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.

Mudaliar S, Polidori D, Zambrowicz B, Henry RR.

Diabetes Care. 2015 Dec;38(12):2344-53. doi: 10.2337/dc15-0642. Review.

PMID:
26604280
17.

Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management "Tune Up" Clinic in Complex Patients.

Morello CM, Christopher ML, Ortega L, Khoan J, Rotunno T, Edelman SV, Henry RR, Hirsch JD.

Ann Pharmacother. 2016 Jan;50(1):8-16. doi: 10.1177/1060028015615586. Epub 2015 Nov 5.

PMID:
26546580
18.

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.

Henry RR, Thakkar P, Tong C, Polidori D, Alba M.

Diabetes Care. 2015 Dec;38(12):2258-65. doi: 10.2337/dc15-1730. Epub 2015 Oct 20.

PMID:
26486192
19.

Activation of G proteins by GIV-GEF is a pivot point for insulin resistance and sensitivity.

Ma GS, Lopez-Sanchez I, Aznar N, Kalogriopoulos N, Pedram S, Midde K, Ciaraldi TP, Henry RR, Ghosh P.

Mol Biol Cell. 2015 Nov 15;26(23):4209-23. doi: 10.1091/mbc.E15-08-0553. Epub 2015 Sep 16.

20.

Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes.

Eckel RH, Henry RR, Yue P, Dhalla A, Wong P, Jochelson P, Belardinelli L, Skyler JS.

Diabetes Care. 2015 Jul;38(7):1189-96. doi: 10.2337/dc14-2629. Epub 2015 Jun 6.

Supplemental Content

Loading ...
Support Center